Kinetics of peripheral blood neutrophils in severe coronavirus disease 2019.
COVID‐19
chemokine
cytokine
emergency myelopoiesis
neutrophil
protease
Journal
Clinical & translational immunology
ISSN: 2050-0068
Titre abrégé: Clin Transl Immunology
Pays: Australia
ID NLM: 101638268
Informations de publication
Date de publication:
2021
2021
Historique:
received:
07
01
2021
revised:
08
03
2021
accepted:
08
03
2021
entrez:
10
5
2021
pubmed:
11
5
2021
medline:
11
5
2021
Statut:
epublish
Résumé
Emerging evidence of dysregulation of the myeloid cell compartment urges investigations on neutrophil characteristics in coronavirus disease 2019 (COVID-19). We isolated neutrophils from the blood of COVID-19 patients receiving general ward care and from patients hospitalised at intensive care units (ICUs) to explore the kinetics of circulating neutrophils and factors important for neutrophil migration and activation. Multicolour flow cytometry was exploited for the analysis of neutrophil differentiation and activation markers. Multiplex and ELISA technologies were used for the quantification of protease, protease inhibitor, chemokine and cytokine concentrations in plasma. Neutrophil polarisation responses were evaluated microscopically. Gelatinolytic and metalloproteinase activity in plasma was determined using a fluorogenic substrate. Co-culturing healthy donor neutrophils with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) allowed us to investigate viral replication in neutrophils. Upon ICU admission, patients displayed high plasma concentrations of granulocyte-colony-stimulating factor (G-CSF) and the chemokine CXCL8, accompanied by emergency myelopoiesis as illustrated by high levels of circulating CD10 Our study provides detailed insights into the kinetics of neutrophil phenotype and function in severe COVID-19 patients, and supports the concept of an increased neutrophil activation state in the circulation.
Identifiants
pubmed: 33968405
doi: 10.1002/cti2.1271
pii: CTI21271
pmc: PMC8082714
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e1271Investigateurs
Alexander Wilmer
(A)
Philippe Meersseman
(P)
Diether Lambrechts
(D)
Michael Casaer
(M)
Steffen Rex
(S)
Nathalie Lorent
(N)
Karin Thevissen
(K)
Kim Martinod
(K)
Informations de copyright
© 2021 The Authors. Clinical & Translational Immunology published by John Wiley & Sons Australia, Ltd on behalf of Australian and New Zealand Society for Immunology, Inc.
Déclaration de conflit d'intérêts
The authors declare that no conflict of interest exists.
Références
Sci Immunol. 2018 Dec 7;3(30):
pubmed: 30530726
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Clin Infect Dis. 2020 Jul 28;71(15):762-768
pubmed: 32161940
Trends Immunol. 2019 Jul;40(7):565-583
pubmed: 31160207
N Engl J Med. 2006 May 11;354(19):2034-45
pubmed: 16687716
Nat Rev Immunol. 2011 Jul 25;11(8):519-31
pubmed: 21785456
JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
J Biol Chem. 2001 Aug 10;276(32):29839-45
pubmed: 11390394
Front Public Health. 2020 Jun 18;8:299
pubmed: 32626680
Pharmacol Ther. 2010 Jul;127(1):1-8
pubmed: 20451553
Euro Surveill. 2020 Jan;25(3):
pubmed: 31992387
Trends Immunol. 2019 Jul;40(7):584-597
pubmed: 31153737
Curr Opin Hematol. 2016 Jan;23(1):5-10
pubmed: 26554891
Science. 2020 May 1;368(6490):473-474
pubmed: 32303591
Am J Hematol. 2020 Jul;95(7):834-847
pubmed: 32282949
Trends Immunol. 2003 Jun;24(6):302-6
pubmed: 12810105
Immunity. 2019 Feb 19;50(2):288-301
pubmed: 30784577
J Transl Med. 2020 May 20;18(1):206
pubmed: 32434518
JCI Insight. 2020 Jun 18;5(12):
pubmed: 32427582
Immunol Today. 1998 Apr;19(4):182-9
pubmed: 9577095
Ann Intern Med. 2020 Aug 18;173(4):268-277
pubmed: 32374815
JCI Insight. 2021 Jan 11;6(1):
pubmed: 33232303
Blood. 2004 Jul 15;104(2):565-71
pubmed: 15054039
Trends Immunol. 2019 Jul;40(7):648-664
pubmed: 31155315
EMBO J. 2006 Sep 6;25(17):3934-42
pubmed: 16917503
Blood. 2017 Mar 9;129(10):1343-1356
pubmed: 28053192
J Leukoc Biol. 2021 Jan;109(1):67-72
pubmed: 32869342
Expert Rev Clin Immunol. 2014 May;10(5):593-619
pubmed: 24678812
Clin Chem Lab Med. 2020 Jun 25;58(7):1021-1028
pubmed: 32286245
Oncotarget. 2016 Sep 20;7(38):62439-62459
pubmed: 27566567
Nat Med. 2020 Jul;26(7):1070-1076
pubmed: 32514174
Immunity. 2019 Feb 19;50(2):390-402.e10
pubmed: 30709741
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Sci Rep. 2017 Mar 08;7:43568
pubmed: 28272395
Haematologica. 2015 Aug;100(8):1005-13
pubmed: 26001794
Int Immunopharmacol. 2020 Jul;84:106504
pubmed: 32304994
Cell. 2020 Sep 17;182(6):1419-1440.e23
pubmed: 32810438
Cell. 2020 Sep 17;182(6):1401-1418.e18
pubmed: 32810439
J Hematother Stem Cell Res. 2002 Jun;11(3):513-21
pubmed: 12183836
Allergy. 2020 Jul;75(7):1730-1741
pubmed: 32077115
Front Immunol. 2018 Jun 11;9:1298
pubmed: 29942307
J Leukoc Biol. 2018 May;103(5):829-838
pubmed: 29462505
Nat Rev Immunol. 2014 May;14(5):302-14
pubmed: 24751955
Physiol Rev. 2019 Apr 1;99(2):1223-1248
pubmed: 30758246
Adv Biol Regul. 2020 Aug;77:100741
pubmed: 32773102
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651
J Exp Med. 2020 Jun 1;217(6):
pubmed: 32302401
PLoS Pathog. 2014 Mar 13;10(3):e1003993
pubmed: 24626392
Int J Antimicrob Agents. 2020 Aug;56(2):106017
pubmed: 32437920
Cell Mol Immunol. 2020 May;17(5):433-450
pubmed: 32238918